CN115135333A - Composition for improving hyperuricemia comprising Rhus succedanea extract - Google Patents
Composition for improving hyperuricemia comprising Rhus succedanea extract Download PDFInfo
- Publication number
- CN115135333A CN115135333A CN202080097581.9A CN202080097581A CN115135333A CN 115135333 A CN115135333 A CN 115135333A CN 202080097581 A CN202080097581 A CN 202080097581A CN 115135333 A CN115135333 A CN 115135333A
- Authority
- CN
- China
- Prior art keywords
- extract
- uric acid
- composition
- hyperuricemia
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 52
- 244000044283 Toxicodendron succedaneum Species 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 31
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 52
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 49
- 229940116269 uric acid Drugs 0.000 claims abstract description 49
- 108010093894 Xanthine oxidase Proteins 0.000 claims abstract description 37
- 102100033220 Xanthine oxidase Human genes 0.000 claims abstract description 36
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 21
- 235000013376 functional food Nutrition 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 201000005569 Gout Diseases 0.000 claims description 16
- 230000003078 antioxidant effect Effects 0.000 claims description 14
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 43
- 239000004922 lacquer Substances 0.000 abstract description 9
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 5
- 241000208340 Araliaceae Species 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 2
- 238000007599 discharging Methods 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 235000008434 ginseng Nutrition 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 25
- 239000000126 substance Substances 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 17
- 229960003459 allopurinol Drugs 0.000 description 15
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 15
- 239000003981 vehicle Substances 0.000 description 15
- 239000003973 paint Substances 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 13
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 12
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 12
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 229940074393 chlorogenic acid Drugs 0.000 description 12
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 12
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 12
- 235000001368 chlorogenic acid Nutrition 0.000 description 12
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 12
- NTDFJPCHHGBHCO-UHFFFAOYSA-N 7,9-dihydro-3H-purine-2,6,8-trione Chemical compound OC1=NC(O)=C2NC(O)=NC2=N1.N1C(=O)NC(=O)C2=C1NC(=O)N2 NTDFJPCHHGBHCO-UHFFFAOYSA-N 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 11
- 229960003081 probenecid Drugs 0.000 description 11
- 102000004316 Oxidoreductases Human genes 0.000 description 10
- 108090000854 Oxidoreductases Proteins 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 208000009911 Urinary Calculi Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000001543 one-way ANOVA Methods 0.000 description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- GRTOGORTSDXSFK-XJTZBENFSA-N ajmalicine Chemical compound C1=CC=C2C(CCN3C[C@@H]4[C@H](C)OC=C([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 GRTOGORTSDXSFK-XJTZBENFSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- -1 specifically Substances 0.000 description 5
- 230000002485 urinary effect Effects 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 241000159241 Toxicodendron Species 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 4
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 4
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 4
- 235000005493 rutin Nutrition 0.000 description 4
- 229960004555 rutoside Drugs 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 4
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010060891 General symptom Diseases 0.000 description 3
- 208000000913 Kidney Calculi Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010029148 Nephrolithiasis Diseases 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 235000014220 Rhus chinensis Nutrition 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229930004725 sesquiterpene Natural products 0.000 description 3
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- KJHJAABRDASKAF-UHFFFAOYSA-N 3,7-dihydropurine-2,6-dione Chemical compound OC1=NC(O)=C2N=CNC2=N1.O=C1NC(=O)NC2=C1NC=N2 KJHJAABRDASKAF-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000208225 Rhus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940116731 Uricosuric agent Drugs 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229950000193 oteracil Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000004144 purine metabolism Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001751 uricolytic effect Effects 0.000 description 2
- 239000003383 uricosuric agent Substances 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- YOVSPTNQHMDJAG-QLFBSQMISA-N β-eudesmene Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(=C)C)CC[C@]21C YOVSPTNQHMDJAG-QLFBSQMISA-N 0.000 description 2
- OUWRASYSJBAWAF-PPTFASHNSA-N (7as)-3,3,4,7a-tetramethyl-1,2,3a,3b,4,6,6a,7-octahydrocyclopenta[a]pentalen-5-one Chemical compound C1CC(C)(C)C2C3C(C)C(=O)CC3C[C@@]21C OUWRASYSJBAWAF-PPTFASHNSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000392544 Dendropanax morbifer Species 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 235000008586 Hovenia Nutrition 0.000 description 1
- 241000405398 Hovenia Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 244000197975 Solidago virgaurea Species 0.000 description 1
- 235000000914 Solidago virgaurea Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000008114 Uric Acid Assay Methods 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- OZQAPQSEYFAMCY-UHFFFAOYSA-N alpha-selinene Natural products C1CC=C(C)C2CC(C(=C)C)CCC21C OZQAPQSEYFAMCY-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229930002878 anthoxanthin Natural products 0.000 description 1
- 150000004637 anthoxanthins Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- YOVSPTNQHMDJAG-UHFFFAOYSA-N beta-helmiscapene Natural products C1CCC(=C)C2CC(C(=C)C)CCC21C YOVSPTNQHMDJAG-UHFFFAOYSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007253 cellular alteration Effects 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IEICDHBPEPUHOB-UHFFFAOYSA-N ent-beta-selinene Natural products C1CCC(=C)C2CC(C(C)C)CCC21C IEICDHBPEPUHOB-UHFFFAOYSA-N 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- RONWGALEIBILOG-VMJVVOMYSA-N quinine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 RONWGALEIBILOG-VMJVVOMYSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a composition comprising a Rhus succedanea extract as an effective ingredient, and more particularly, to a medical composition or a functional food composition having a preventive, ameliorating and/or therapeutic effect on hyperuricemia. According to the invention, the limitation of the existing product is overcome, and a new hierarchical technology for improving the hyperuricemia which is a natural raw material and has two effects of inhibiting the activity of xanthine oxidase and discharging uric acid can be obtained. And, modern scientific research on pharmacological efficacy of korean indigenous resources, separation and purification of active ingredients, safety, toxicity research, etc. is systematically performed, thereby ensuring that korean indigenous biological resources can be developed as a basis for international famous brands, like ginseng. Moreover, the application range can be expanded to various industrial fields such as the application degree of natural medicinal raw materials and health functional foods using the yellow lacquer extract.
Description
Technical Field
The present invention relates to a composition comprising a Rhus succedanea extract as an active ingredient, and more particularly, to a pharmaceutical composition or a functional food composition having a preventive, ameliorating and/or therapeutic effect on hyperuricemia.
Background
Uric acid (C) 5 H 4 N 4 O 3 ) Is a process of purine metabolism in vivo, which is caused by hypoxanthine (hypoxanthine; c 5 H 4 N 4 O) or anthoxanthin produced by xanthine oxidase or xanthine dehydrogenase, approximately 70% of uric acid in blood is produced by endogenous purine metabolism based on cellular alterations (turn-over), 30% is formed by purine taken through diet, and most is excreted through the kidney.
Under such conditions of increased uric acid formation or decreased excretion, the uric acid concentration in blood increases to 7.0mg/dL or more in men and 6.5mg/dL or more in women, which is defined as hyperuricemia. It is known that an increase in uric acid concentration is responsible for gout (gout), which induces inflammatory reaction due to precipitation of urate crystals (urate crystals) in the joint membrane, and recently, an interesting mechanical or clinical study on the correlation between uric acid and renal diseases, cardiovascular diseases including hypertension, and metabolic syndrome and onset/exacerbation of diabetes has been published.
On the other hand, gout, a typical disease occurring in a human body with hyperuricemia, is a chronic systemic metabolic disease in which white blood cells phagocytose uric acid crystals generated by various factors by immune reaction, causing recurrent paroxysmal arthritis of joints and tissues around the joints, and when uric acid is continuously excessive, joint disorders are caused by accumulated uric acid nodules. As described below, uric acid is formed during purine decomposition, and excessive production of uric acid causes gout.
Gout clinically causes acute gout attack, chronic arthritis, gout nodules and the like, and also becomes a cause of various diseases such as uric acid urinary calculi, chronic kidney diseases and the like. Recently, the incidence of obesity, kidney diseases, hypertension, hyperuricemia caused by increased use of diuretics such as thiazide and aspirin, and gout caused by hyperuricemia has been rapidly increasing due to aging and westernization of dietary life. Therefore, gout patients are often accompanied by chronic diseases such as obesity, diabetes, hypertension, hyperlipidemia, and metabolic syndrome, and are known to have a high risk of cardiovascular diseases in particular.
Such gout is diagnosed as the presence of uric acid crystals phagocytosed by polymorphonuclear leukocytes or accumulated in tissues in lubricating fluids or tissues of joints, and recently, dual energy computed tomography, ultrasound, and the like have been used for diagnosis to improve the diagnosis rate. The rate of males is 10 times that of females and up to 21 times that of 30 years old as reported by Korean gout medical record.
In addition, excessive uric acid can also cause urinary calculus (kidney stone, ureteral stone). Urinary calculi are diseases in which many substances such as uric acid and calcium are not properly excreted by urination during digestion, but stay in the kidneys and are largely crystallized to cause symptoms of disorders, and are mostly urinary calculi because urinary ducts are elongated and most frequently clogged. The kidney diseases caused by hyperuricemia are classified into kidney stones and chronic uric acid kidney diseases, and the kidney stones caused by uric acid account for 5-10% of the whole urinary calculi. 80% of uric acid lithangiuria is composed of only uric acid crystals, and the remaining uric acid lithangiuria increases calcium oxalate or calcium phosphate in uric acid crystal nuclei, thereby causing lithangiuria.
As a therapeutic agent for ameliorating or treating such hyperuricemia, xanthine oxidase inhibitors (xanthine oxidase inhibitors), Uricosuric agents (uric acid excretion), Uricolytic agents (urozyme), and the like are available.
The xanthine oxidase inhibitor is used for inhibiting uric acid synthesis, and when the xanthine oxidase inhibitor is used, uric acid metabolism is inhibited, uric acid concentration in blood is reduced, and hyperuricemia and gout can be treated. The uricosuric agent acts on the proximal tubule of the kidney to inhibit the reabsorption of uric acid, thereby functioning to promote the excretion via urine. The uricolytic agent is an enzyme that oxidizes uric acid into allantoin (allantoin), which has higher solubility than uric acid and is easily excreted through the kidney.
Disclosure of Invention
Technical problem
In the prior art for treating the above hyperuricemia, the xanthine oxidase inhibitory activity and uric acid discharge effects were separated. The risk of death of febuxostat, one of gout therapeutic agents that acts as a mechanism to reduce uric acid values in blood, is under debate. Thus, there is an urgent need to develop uric acid-emitting products without side effects.
Specifically, there is an urgent need to develop a new hierarchical technique for improving hyperuricemia, which is a natural raw material, and which overcomes the limitations of the existing products and has 2 effects of inhibiting xanthine oxidase and releasing uric acid.
Also, since a large amount of Reactive Oxygen Species (ROS) is formed during the production of uric acid and causes inflammation and tissue damage, the ingredient having an antioxidant effect contributes to the symptoms and treatment of hyperuricemia patients, and thus the development of products containing the ingredient is effective.
Means for solving the problems
In order to solve the above problems, the present invention provides a composition for preventing, improving and/or treating hyperuricemia comprising an extract of Rhus succedanea.
In an embodiment of the present invention, the composition can simultaneously perform the xanthine oxidase inhibitory activity and the uric acid excretion function.
In one embodiment of the present invention, the composition can perform antioxidant activity.
In one embodiment of the present invention, the composition can exhibit functions of preventing, improving and/or treating gout, urinary calculi and kidney diseases derived from hyperuricemia.
In an embodiment of the present invention, the composition may be a functional food composition.
In an embodiment of the present invention, the Rhus succedanea extract can be extracted according to water or a mixture of water and ethanol.
ADVANTAGEOUS EFFECTS OF INVENTION
According to the invention, a novel 2-level hyperuricemia improving technology which overcomes the limit of the existing product and has the effects of inhibiting the activity of xanthine oxidase and discharging uric acid can be obtained.
And, modern scientific research on pharmacological efficacy of korean indigenous resources, separation and purification of active ingredients, safety, toxicity research, etc. is systematically performed, thereby ensuring that korean indigenous biological resources can be developed as a basis for international famous brands, like ginseng.
Moreover, the application range can be expanded to various industrial fields such as the application degree of natural medicinal raw materials and health functional foods using the yellow lacquer extract.
Drawings
Fig. 1 is a graph looking at the results of Xanthine Oxidase (XO) inhibitory activity of a chinese goldenrod extract. CGA is chlorogenic acid (chlorogenic acid) which is one of the marker ingredients.
FIG. 2 shows the measurement of serum uric acid value in animal experiment.
FIG. 3 shows the results of the activity of intrahepatic Xanthine Oxidase (XO) in animal experiments.
Detailed Description
The following detailed description will be given of embodiments of the present invention so that those skilled in the art to which the present invention pertains can easily carry out the present invention. Embodiments of the present invention are provided to more fully explain the present invention to those skilled in the art. Therefore, the embodiment of the present invention can be modified in various other embodiments, and the scope of the present invention is not limited to the embodiments described below.
Throughout the description of the present invention, when some parts "include" some structural elements, it means that other structural elements may be included without excluding other structural elements unless otherwise stated.
Throughout the description of the present invention, when certain steps are "on" or "before" other steps, this may include the case where certain steps have a direct time series relationship with other steps, and may include the same right where the order of two steps may change the indirect time series relationship of the time series as in the case of a mixed step after each step.
The terms "about," "substantially," and the like, as used throughout the specification are used in the sense of referring to the inherent manufacturing and material tolerances, are used in the sense of the values or close to the values in order to prevent an ill-intentioned attacker from illegally utilizing the disclosure of the correct or absolute values that are helpful in understanding the present invention. The term "performing" or "step" used throughout the present specification does not mean "step for" or "step" used in "step".
Rhus succedanea (Dendropanax morbifera) is an evergreen broad-leaved forest belonging to Araliaceae (Araliaceae), a subtropical tree species that is autogenous and cultivated only in southwest coast and island regions of the southwest of the whole Roots. The resin of the yellow lacquer is golden, has strong heat resistance, durability and water resistance, good adhesiveness and luster, and is used as a natural coating of the traditional handicraft articles and a raw material of folk medicines since ancient times. Further, it has been reported that the yellow lacquer contains not only essential oil components such as sesquiterpene, but also various components such as arachidic acid, palmitic acid, arginine, etc., and has effects of arteriosclerosis, improvement of liver function, promotion of oxidation-resistant bone regeneration, enhancement of immunity, antibacterial, anticancer, etc. The yellow lacquer is described as an edible raw material (leaf, stem, root) in the food code of the food and drug security hall, and is not limited in industrial application.
The yellow paint is a korean indigenous tree species, and its blood circulation improvement (anti-arteriosclerosis effect), liver function improvement, hard tissue (bone and tooth) regeneration effect, anti-diabetes effect, anti-hypertension effect, anti-cancer effect, anti-oxidation effect, skin tissue regeneration, immunity enhancement, neuroleptic effect, antibacterial activity and the like are disclosed in korean medical books and modern medicine, and it is suitable as a new material for high value-added food. However, the research on the composition of the yellow paint has been mainly focused on the analysis of essential oils and fatty acids (fatty acid) components such as β -celecene (β -selinene) and capnellane-8-one to which sesquiterpene (sesquiterpene) having 2 ring structures belongs contained in the sap of yellow paint used as a coating material, which is in an incomplete state in terms of the correlation or effective components with the pharmacological efficacy or functionality of the components contained in leaves, stems, barks, etc.
The present invention is characterized by providing a composition for ameliorating hyperuricemia, which utilizes the yellow sumac-derived component. The inventor confirms that the Rhus succedanea extract has an inhibiting effect and an antioxidant effect on xanthine oxidase, and also confirms the effect of reducing the uric acid value in blood of the Rhus succedanea extract through simple clinical tests. Furthermore, the effect of reducing the uric acid concentration in blood was also confirmed using an animal model. Thus, in the present invention, a pharmaceutical and/or functional food composition having a xanthine oxidase inhibitory effect, a uric acid emitting effect, and an antioxidant effect of the Rhus succedanea extract can be provided.
The composition for improving hyperuricemia according to an embodiment of the present invention may include an extract from a tree of toxicodendron amurense and a leaf of toxicodendron amurense (hereinafter, also referred to as "toxicodendron amurense extract"). In the present invention, the trees of Rhus succedanea may mean the bark of Rhus succedanea, etc. The leaves and/or stems of raw Rhus succedanea can be used as they are, but dried leaves and/or stems of dried Rhus succedanea can also be used in the form of dried crude drugs.
In one embodiment of the present invention, the solvent of the extract of the tree and leaf of the resina toxicodendri is a mixed solvent of water and ethanol. More specifically, the above-mentioned mixed solvent may mix water and ethanol at a weight ratio of 6:4 to 8:2, and preferably may mix at a ratio of 7: 3.
The pharmaceutical composition of the present invention can be formulated according to the formulation standards of conventional pharmaceutical preparations in the food and medicine safety agency (KFDA). Preferably, the yellow lacquer extract or the yellow lacquer liquid fermentation metabolite is diluted by mixing with a pharmaceutically acceptable carrier by a conventional method according to an administration method, an administration form and a therapeutic purpose, or enclosed in a carrier in a container form.
The pharmaceutical composition includes oral preparations, injections, suppositories, transdermal administration, and nasal administration, but can be formulated and administered in any dosage form not limited thereto, and preferably can be formulated in oral administration dosage forms such as liquid, suspension, powder, granules, tablets, capsules, pills, and extracts.
When formulated in the above-mentioned respective dosage forms, the preparations may be prepared by adding pharmaceutically acceptable carriers or additives required in the preparation of the respective dosage forms. Typically, when formulated into an oral dosage form, the carrier may be selected from 1 or more of diluents, lubricants, binders, disintegrants, sweeteners, stabilizers and preservatives, and the additive may be selected from 1 or more of flavors, vitamins and antioxidants.
The above carriers and additives can be pharmaceutically acceptable carriers and additives, specifically, lactose, corn starch, soybean oil, microcrystalline cellulose or mannitol is preferable as diluent, magnesium stearate or talc is preferable as lubricant, and polyvinylpyrrolidone or hydroxypropyl cellulose is preferable as binder. Further, as the disintegrating agent, calcium carboxymethylcellulose, sodium starch glycolate, polacrilin potassium, or crospovidone is preferable, as the sweetening agent, white sugar, fructose, sorbitol, or aspartame is preferable, as the stabilizing agent, sodium carboxymethylcellulose, β -cyclodextrin, white wax, or xanthan gum is preferable, and as the preservative, methyl paraben, propyl paraben, or potassium sorbate is preferable.
In addition to the above components, as known additives, natural flavors such as plum flavor, lemon flavor, pineapple flavor, and vanilla flavor, natural fruit juice, chlorophyllin, and natural colors such as flavonoids, and sweet components such as fructose, honey, sugar alcohol, and granulated sugar, and sour agents such as citric acid and sodium citrate may be mixed for enhancing taste.
The pharmaceutical composition can be administered in a dose of 1 day total dose of 1 to 100g/kg of Rhus succedanea extract and 0.01 to 50g/kg of Rhus succedanea crude drug, as effective components, in several times at will based on adults, in order to obtain hyperuricemia improving effect. The dose can be increased or decreased as appropriate depending on the type of disease to be treated or prevented, the degree of progression of the disease, the route of administration, sex, age, body weight, and the like.
In another aspect, a functional food comprising the Rhus succedanea extract according to the present invention described above is provided. In the present invention, the "functional food" refers to a food prepared and processed using functional raw materials or ingredients useful for human bodies according to laws related to health functional foods.
Conventional functional health foods can be formulated in the dosage forms of conventional functional foods known in the art using a dietetically acceptable carrier. The functional food can be prepared into, for example, powders, granules, tablets, capsules, suspensions, emulsions, syrups, liquids, aerosols, extracts, and the like. As the above-mentioned bromatologically allowable carrier or additive, any carrier or additive known to be usable in this technical field can be used in the preparation of a dosage form to be prepared.
Hereinafter, the present invention will be described more specifically by way of examples according to one embodiment of the present invention, which should not be construed as limiting the scope of the present invention.
1.Xanthine Oxidase (XO) inhibitory activity
Experiments for the inhibitory activity of the extract of Chinese sumac and xanthine oxidase (xanthine oxidase) as an active ingredient were performed according to the method of Stire and Corte Della. To 0.1mL of extracts (0.5 to 8.0mg/mL) and 0.6mL of 0.1M potassium phosphate buffer (pH 7.5) having different concentrations, 0.2mL of a xanthine (xanthine) base solution having a concentration of 2mM and 0.1mL of a xanthine oxidase (0.2uint/mL) were added, and then, after 0.1mL of a xanthine oxidase (0.2uint/mL) was added, 1mL of NHCl was added after a reaction was performed at 37 ℃ for 15 minutes, and after the reaction was stopped, the amount of uric acid produced in the reaction solution was calculated by measuring absorbance at 290nm using an ultraviolet-visible spectrophotometer (Optizen POP, CM Science, Busan, Korea). As a positive control group, allopurinol (allopurinol), yellow, which is an inhibitor of xanthine oxidase (xanthene oxidase) and is used in the treatment of pain was usedInhibition activity (%) of purine oxidase was calculated from IC according to the following formula 50 The values are represented.
Inhibitory effect (Inhibition effect) (%) - [ 1- (a-B)/C) ] × 100
(A: absorbance after reaction of a sample of the extract and an enzyme solution added to a Xanthine (Xanthine) solution (2mM)
B: the absorbance after the reaction was measured by adding 0.1mL of distilled water to A instead of adding the enzyme solution
C: adding distilled water 0.1mL instead of the extract to A, absorbance after reaction)
The results of examining the XO inhibitory activity of the sumac extract and the active ingredients are shown in fig. 1. As a result of comparing the hot water extract of resina xanthiifolia with the alcohol extracts of different concentrations, it was confirmed that the higher the alcohol concentration, the higher the XO inhibitory activity. As a result of comparing the XO inhibitory activities based on the shelf life of the yellow paints, the extract from the yellow paints within 3 months (New) after collection exhibited an XO inhibitory activity about 2 times higher than that of the extract from the yellow paints 1 year or more (Old) after collection, and it was confirmed that the activity exhibited differences according to the shelf life. As a result of confirming XO inhibitory activity of chlorogenic acid (chlorogenic acid), which is one of the index components of the Rhus succedanea extract, the IC was 69.07. mu.g/ml 50 Although having a lower activity than that of allopurinol (allopurinol) of the positive control group, it was judged that there was no problem in setting it as an index component of the yellow lacquer extract.
2. Antioxidant effect
DPPH scavenging efficacy 2-1
DPPH clearance activity assay is an experiment used in the determination of antioxidant activity. The reducing power (antioxidant power) of a substance is measured indirectly by measuring the degree of reduction of DPPH radicals caused by the reaction with a predetermined amount of a sample solution using a stable free radical 2, 2-Diphenyl-1-picrylhydrazino (2,2-Diphenyl-1-picryl, DPPH) which is a model of unsaturated fatty acid radicals, using a Spectrophotometer (Spectrophotometer). Namely, 2, 2-diphenyl-1-picrylhydrazino (2, 2-Dipheny)l-1-picryl hydrazyl, DPPH) is a chemically stable water-soluble radical, which is a violet compound exhibiting characteristic light absorption at 517nm, and is very stable in an organic solvent such as ethanol, and when it encounters a substance having an antioxidant arc shape, electrons are released to scavenge the radical (DPPH), and the radical changes from the original violet to yellow, thereby having an advantage that the oxidation activity can be easily observed by the naked eye. Vitamin C (vitamin C) (ascorbic acid) known as a control group was used for comparison, samples and DPPH were dissolved in DMSO and then diluted in methanol, and 90. mu.l of DPPH (100. mu.M) and 10. mu.l of samples were put in a 96-well culture plate and reacted at 37 ℃ for 10 minutes, and then the absorbance was measured at 517 nm. DPPH radical scavenging Activity by IC 50 The values are represented.
2-2 determination of antioxidant efficacy by DCFH-DA assay
The DCFH-DA assay is a method used for measuring the amount of Reactive Oxygen Species (ROS) in cells or the intracellular ROS-scavenging ability of a specific substance, and uses 2 '7' diacetate (DCFH-DA) of a probe (probe) that exhibits fluorescence that allows cell permeation. DCFH-DA diffuses into cells and is converted to 2 '7' (DCFH) by intracellular esterase (esterase), and this substance is used for intracellular antioxidant experiments by utilizing the principle that ROS is rapidly converted to 2 '7' (DCF) exhibiting fluorescence.
As the cell line used in the experiment, adriamycin (doxorubicin) -resistant cell line AML-2/DX100, which is leukemia cell AML-2 in which catalase (catalase) activity is expressed relatively rarely, was used. Washing 2 times of AML-2/DX100 cells with PBS 1x10 5 After cells/ml, 200. mu.l of each cell was dispensed into each well (well), and the dispensed cells were filled with samples at different concentrations in advance, and DCFH-DA was filled in 1. mu.H 2 O 2 After induction of active oxygen at 4mM, at 5% CO 2 After 30 minutes of reaction in an incubator at 37 ℃, the degree of fluorescence (excitation)485nm and the emission wavelength (emission wavelength)530nm) were measured. DCFH-DA free radical scavenging capacity (%), will be based on H 2 O 2 The value of fluorescence cleared by the drug was calculated as a percentage, with the value of increased fluorescence set as 100.
2-3. determination of antioxidant efficacy test results
TABLE 1
DW: hot water extract EtOH: alcohol extract
New: within 3 months after collection
Old: collecting for more than 1 year
Shows DPPH clearance efficacy and antioxidant efficacy of the lacquer extract confirmed using the DCFH-DA assay (table 1).
The DPPH radical scavenging effect was similar to the results of XO inhibitory activity, and it was confirmed that the higher the alcohol content and the shorter the storage period, the higher the activity was exhibited. However, the activity of the 70% alcohol extract was rather low in terms of the radical scavenging ability of DCFH-DA, and a similar pattern was observed in that the activity was higher as the storage period was shorter.
3. Analysis of index substance
In order to confirm the content of the active ingredient of the Rhus succedanea extract, the results of analyzing the contents of chlorogenic acid (CGA) and rutin by HPLC-MS/MS are shown (Table 2).
As the alcohol concentration was increased, the content of chloregenic acid (CGA) was increased, and the content of CGA as an index substance was increased, so that it was confirmed that XO inhibitory activity and antioxidant effect were high. Furthermore, since the extract from the yellow paint (New) within 3 months after collection has a CGA content 2 times or more higher than that of the extract from the yellow paint (Old) after 1 year or more, it was confirmed that the useful component was denatured or disappeared when the extract was stored for a long period of time after collection of the yellow paint. The content of rutin as the active ingredient of the yellow paint is similar to the content of CGA.
TABLE 2
| Chlorogenic acid content (Fg/g) | Rutin (Rutin) content (Fg/g) | |
| Yellow paint DW | 6,424±208 | 10,391±59 |
| Yellow paint 30% EtOH | 13,253±237 | 16,392±218 |
| Yellow paint 50% EtOH | 17,419±297 | 23,737±308 |
| Yellow paint 70% EtOH | 21,464±119 | 29,524±139 |
| New30％EtOH | 14,566±375 | 33,963±369 |
| Old30％EtOH | 3,7913±91 | 8,954±44 |
4. Animal experiments
Test substance I: 30% ethanol extract of Rhus succedanea (leaf, stem)
Test substance II: rhus succedanea (leaf, stem) hot water extract
Control substance I: probenecid (Probenecid)
Control substance II: allopurinol (Allopurinol)
Excipient: sterilized Water for injection (distilled Water)
Inducing substance: potassium oxonate (Potasumoxonate)
4-1. animal information
TABLE 3
Animals were acclimatized in an animal room for 8 days of testing after being admitted and general symptoms were observed more than 1 time per day. Animals were identified during acclimation using tail labeling with a red oily marker pen. During dosing and observation, tail labeling with a black oily marker pen was used for identification.
-attaching a color-differentiated capacity physical identification card to the feeding box, and attaching a unique number to the feeding box.
-attaching test identification papers at the entrance of the housing.
Animal experimental ethics were approved by the institutional animal care committee of chem on, strain. (examination number: 2019-10-001)
4-2. feeding environment
Animals were housed in Kyogi Hovenia bioscience animal housing area No. 4 maintained at a temperature of 23 + -3 deg.C, a relative humidity of 55 + -15%, a ventilation frequency of 10-20 times/hr, an illumination time of 12 hours (8 am-8 pm off), and an illumination of 150 Lux.
-measuring the temperature and relative humidity hourly using a computer system, periodically measuring the number of ventilations and the illuminance.
During the experiment, there were no abnormalities affecting the test results.
The rats were allowed free access to rodent solid feed (Teklad certified animal vertebral 18% protein rodent diet; 2918C; ENVIGO, UK).
The tap water sterilized by means of an ultraviolet sterilizer and a microfiltration device was put into a drinking bottle made of polycarbonate, and the water was freely taken by rats. Water quality inspection was performed by the public health environment research institute of Kyogi province (Changan district, Ba Changchua road 95, Kyogi province, Hydrogen), which was suitable for the water quality standard of drinking water.
-use after autoclaving the mat.
The results of the pollutant test confirmation show that there are no abnormalities affecting the test results.
The cells were housed in a stainless steel net-made feeding box (W235 x L380 x H175 mm) in a number of 4 cells per feeding box during acclimatization, administration and observation.
-rearing boxes and water bottles, changed more than 1 time per week.
4-3 test group composition, dosage setting, grouping and administration
TABLE 4
G1: normal group (disabled water, n ═ 8) G2: vehicle control group (Distilled water, n ═ 8)
G3: control substance I administration group (Probenecid, 50mg/kg, n-8)
G4: control substance II administration group (Allopurinol, 50mg/kg, n ═ 8)
G5: test substance I administration group (DM30EE, 50mg/kg, n ═ 7)
G6: test substance I administration group (DM30EE, 100mg/kg, n-7 or 8)
G7: test substance I administration group (DM30EE, 200mg/kg, n ═ 8)
G8: test substance II administration group (DMWE, 200mg/kg, n 7or 8)
G2-G8: in the group induced by hyperuricemia,
the amount of the test substance to be administered is set based on information provided by the test requester.
Grouping of animals was performed as follows. Animals close to the average body weight were selected as required and randomly assigned according to the ordered body weights so that the average body weight of each group was maximally evenly distributed to the number specified in the "test group composition" table.
The dosing protocol is as follows.
TABLE 5
| Route of administration and reasons for selection | Oral administration employs a clinically pre-determined route. |
| Number and duration of administration | 1 time/day for 7 days, and 1 hour after the administration of the inducing substance on the day of the administration of the inducing substance. |
| Dose calculation for drug administration | Based on the body weight measured recently, it was calculated as 10 mL/kg. |
| Method of administration | The back head of the animal is fixed, and the drug is directly administered into the stomach by using a syringe provided with a probe. |
4-4. Observation and inspection
1 observation of death, type of general symptoms, day of expression and extent of symptoms during the administration and observation period, recorded on a per individual basis.
-body weight was measured at the time of entry, on the start of group administration and on the planned autopsy days.
On days 1, 3, 5 and 7, 250mg/kg of Potassium Oxazinate (0.5% sodium carboxymethylcellulose) with0.1M sodium acetate (sodium acetate) pH 5) was injected intraperitoneally twice to induce hyperuricemia.
4-5, dissecting autopsy and determining items
On day 7, 1 hour after the administration of Potassium Oxonate (Potaspotassium oxonate), the test substances are administered and the animals are transferred to metabolism cages.
Urine was collected within 2 hours after administration of the test substance, and autopsy was performed.
-performing a posterior vena cava blood sampling.
Perfusion with Saline (Saline) is performed, removing the liver.
The liver tissue and serum were kept in a deep freezer until analysis.
Uric acid (Uric acid) was measured by serum and urine using a kit (kit) (Bio Vision, K608).
The Xanthine oxidase (xanthene oxidase) inhibitory activity was determined by dissecting liver tissues and sera removed at necropsy using a kit (kit) (Sigma Aldrich, MAK 078).
4-6 statistical analysis
The results of the assay were analyzed using SPSS Statistics 12.0K for Medical Science to examine the significance between the normal group (G1), the control substance-administered group (G3-G4), and the test substance-administered group (G5-G8) and the vehicle control group (G2). The test substance I administration group (G5-G7) was examined for significance by ONE-WAY ANOVA (ONE-WAY ANOVA), and the control substance administration group (G3-G4) and the test substance II administration group (G8) were examined for significance by Student's t-test. When P <0.05, it was judged to be statistically significant.
4-7, animal experiment results
i) General symptoms
No abnormal symptoms or death due to the test substances were observed.
ii) uric acid assay results
Serum uric acid (uricc acid) assay results, a statistically significant increase in uric acid (uricc acid) was observed in the vehicle control group (G2) compared to the normal group (G1) (P < 0.01). Compared with the vehicle control group (G2), the 30% ethanol extract of Rhus succedanea (leaves and stems) of 50, 100 and 200mg/kg administered groups (G5-G7) respectively observed serum uric acid (uric acid) decreases of 15.30%, 17.68% and 21.71%, and compared with the vehicle control group (G2), the hot water extract of Rhus succedanea (leaves and stems) of 200mg/kg administered group (G8) observed a statistically significant 26.92% decrease of serum uric acid (uric acid) (P < 0.05). The Probenecid (Probenecid)50mg/kg administered group (G3) showed no change in serum uric acid (uric acid) compared to the vehicle control group (G2), whereas a statistically significant decrease in serum uric acid (uric acid) was observed in the Allopurinol (Allopurinol)50mg/kg administered group (G4) (P < 0.01).
Urine uric acid (uric acid) assay results, a statistically significant decrease in urine uric acid (uric acid) (P <0.05) was observed in the vehicle control group (G2) compared to the normal group (G1). Neither the 30% ethanol extract of Rhus succedanea (leaves, stems) nor the hot water extract of Rhus succedanea (leaves, stems) group administered (G5-G8) showed statistically significant changes compared to the vehicle control group (G2), but exhibited a tendency to decrease urinary uric acid (uric acid). The Probenecid (Probenecid)50mg/kg administered group (G3) exhibited a tendency of reduction, although not exhibiting a statistically significant difference in urinary uric acid (uric acid), compared to the vehicle control group (G2), and a statistically significant decrease in urinary uric acid (uric acid) was observed for Allopurinol (Allopurinol)50mg/kg administered group (G4) (P < 0.05).
The measurement results are shown in FIG. 2.
TABLE 6
The results of the experiment are expressed as [ mean. + -. standard deviation ]. Statistical analysis was performed by boxplot (Box-plot), ONE-WAY analysis of variance (ONE-WAY ANOVA), and Student's t-test. +: has great difference with G1, P <0.05
++: has great difference with G1, P <0.01
*: has great difference with G2, P <0.05
**: has great difference with G2, P <0.01
ii) measurement result of Xanthine oxidase activity
Serum Xanthine oxidase activity (xanthene oxidase activity) assay results no statistically significant change was observed in the vehicle control group (G2) compared to the normal group (G1). The group administered with 30% ethanol extract and hot water extract of Rhus succedanea (leaves, stems) (G5-G8) showed no statistically significant change in serum Xanthine oxidase activity (xanthene oxidase activity) compared to the vehicle control group (G2). Probenecid (Probenecid)50mg/kg dose group (G3) exhibited no statistically significant change in serum Xanthine oxidase activity (xanthene oxidase activity) compared to vehicle control group (G2), whereas a statistically significant decrease in serum Xanthine oxidase activity (xanthene oxidase activity) was observed in Allopurinol (Allopurinol)50mg/kg dose group (G4) (P < 0.01).
Measurement of intrahepatic Xanthine oxidase activity (xanthene oxidase activity) there was no statistically significant change in the vehicle control group (G2) compared to the normal group (G1). Statistically significant reductions in intrahepatic Xanthine oxidase activity (xanthene oxidase activity) were observed for the group administered with 30% ethanol extract of Rhus succedanea (leaves, stems) and 200mg/kg hot water extract of Rhus succedanea (leaves, stems) (G7, G8) compared to the vehicle control group (G2) (P <0.05or P < 0.01). The Probenecid (Probenecid)50mg/kg dosed group (G3) exhibited no statistically significant change in urinary uric acid (uric acid) compared to the vehicle control group (G2), whereas a statistically significant decrease in intrahepatic Xanthine oxidase activity (xanthene oxidase activity) was observed in the Allopurinol (Allopurinol)50mg/kg dosed group (G4) (P < 0.01).
The measurement results are shown in FIG. 3.
TABLE 7
The results of the experiment are expressed as [ mean. + -. standard deviation ]. Statistical analysis was performed by boxplot (Box-plot), ONE-WAY analysis of variance (ONE-WAY ANOVA), and Student's t-test. *: has great difference with G2, P <0.05
**: has great difference with G2, P <0.01
5. Simple clinical test
In the simple clinical test, as a result of confirming the uric acid value in serum when the Rhus succedanea extract was taken, there was no change in the uric acid value but it tended to be higher than the initial one when the period of taking the Rhus succedanea extract was less than 2 months. However, after 3 months, the uric acid value tends to be lower than that at the initial stage. From these results, the following were judged: in order to confirm the therapeutic effect on gout using the toxicodendron chinense nakai extract, long-term administration of 3 months or more is required.
The results of confirming the rate of change of initial uric acid value and uric acid value after 3 months showed a rate of change of-33.33 to 33.33, and the average results confirmed that the uric acid value was decreased by taking 15.75% of the Rhus succedanea extract.
TABLE 8
| Initial stage | After 1 month | After 2 months | After 3 months | Rate of change (early-3 months) | |
| Li xi Cheng | 5.7 | 8 | 6.1 | 7.6 | -33.33 |
| Shu | 6.9 | 7 | 6 | 5.9 | 14.49 |
| Rate of change | 8.8 | 8.3 | 9.9 | 7.2 | 18.18 |
| Su xi drastic | 6 | 6.4 | 5.6 | 4.5 | 25.00 |
| Sun xing Kun | 6.8 | 8.3 | 5.7 | 5.6 | 17.65 |
| Toy tiger | 7.4 | 8.5 | 7.4 | 5.8 | 21.62 |
| Jinxiong | 5.4 | 6.2 | 6.5 | 5 | 7.41 |
| Plum blossom quine | 7.2 | 7.6 | 5.9 | 5.4 | 25.00 |
| Gold stone | 6 | 6.9 | 3.7 | 4 | 33.33 |
| (xi) jin Xu | 10.4 | 10.8 | 9.3 | 7.1 | 31.73 |
| Root of plum | 6.6 | 7.3 | 6.2 | 5.8 | 12.12 |
The scope of the present invention is indicated by the appended claims rather than by the foregoing summary, and it should be construed that the meaning and scope of the claims and all changes and modifications derived from the equivalent concept are included in the scope of the present invention.
Claims (7)
1. A composition for preventing, improving and/or treating hyperuricemia, which is characterized by comprising a Rhus succedanea extract.
2. The composition for preventing, improving and/or treating hyperuricemia according to claim 1, wherein the xanthine oxidase inhibitory activity and the uric acid discharge function can be simultaneously performed.
3. The composition for preventing, improving and/or treating hyperuricemia according to claim 1, wherein an antioxidant activity can be performed.
4. The composition for preventing, improving and/or treating hyperuricemia according to claim 1, wherein a function of preventing, improving and/or treating gout, lithangiuria and kidney diseases derived from hyperuricemia is exhibited.
5. The composition for preventing, improving and/or treating hyperuricemia according to claim 1, wherein the Rhus succedanea extract is extracted according to water or a mixture of water and ethanol.
6. A functional food composition for improving hyperuricemia, which is characterized by comprising an extract of Rhus succedanea.
7. The composition for preventing, improving and/or treating hyperuricemia according to claim 6, wherein the Rhus succedanea extract is extracted according to water or a mixture of water and ethanol.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200023744A KR20210108748A (en) | 2020-02-26 | 2020-02-26 | A composition containing an extract of dendropanax morbifera for hypernricemia |
| KR10-2020-0023744 | 2020-02-26 | ||
| PCT/KR2020/012420 WO2021172678A1 (en) | 2020-02-26 | 2020-09-15 | Composition for ameliorating hyperuricemia comprising dendropanax morbifera lev. extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115135333A true CN115135333A (en) | 2022-09-30 |
Family
ID=77491153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080097581.9A Pending CN115135333A (en) | 2020-02-26 | 2020-09-15 | Composition for improving hyperuricemia comprising Rhus succedanea extract |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR20210108748A (en) |
| CN (1) | CN115135333A (en) |
| WO (1) | WO2021172678A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120101743A (en) * | 2011-02-17 | 2012-09-17 | 동아대학교 산학협력단 | Composition for treating and preventing diabetes containing dendropanoxide from leaves of dendropanax morbifera leveille |
| KR20170027914A (en) * | 2015-09-02 | 2017-03-13 | 농업회사법인 휴림황칠(주) | Composition For Preventing or Treating Gout Containing Extracts or Fermentation Metabolites of Dendropanax morbiferus |
| CN108463231A (en) * | 2015-12-30 | 2018-08-28 | 第三生物赞有限公司 | Prevention and therapeutic composition of the wooden extract of Han You Yellow paints as the climacteric syndrome of active ingredient |
| CN111356468A (en) * | 2017-07-25 | 2020-06-30 | 朝鲜大学校产学协力团 | Composition for preventing or treating fibrotic disease comprising extract of Rhus toxicodendron |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101731903B1 (en) * | 2014-09-19 | 2017-05-02 | 한국생명공학연구원 | Pharmaceutical composition for prevention or treatment of asthma comprising the extracts and fractions of Dendropanax morbifera as active ingredient |
| KR101925420B1 (en) * | 2017-05-15 | 2018-12-07 | 농업회사법인 휴림황칠(주) | Diynoic acid compound and derivatives thereof for uric acid excretion and composition comprising the same |
| KR102002298B1 (en) * | 2017-09-22 | 2019-07-23 | 한국한의학연구원 | Compositions for preventing, ameliorating or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising herbal extracts |
-
2020
- 2020-02-26 KR KR1020200023744A patent/KR20210108748A/en not_active IP Right Cessation
- 2020-09-15 WO PCT/KR2020/012420 patent/WO2021172678A1/en active Application Filing
- 2020-09-15 CN CN202080097581.9A patent/CN115135333A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120101743A (en) * | 2011-02-17 | 2012-09-17 | 동아대학교 산학협력단 | Composition for treating and preventing diabetes containing dendropanoxide from leaves of dendropanax morbifera leveille |
| KR20170027914A (en) * | 2015-09-02 | 2017-03-13 | 농업회사법인 휴림황칠(주) | Composition For Preventing or Treating Gout Containing Extracts or Fermentation Metabolites of Dendropanax morbiferus |
| CN108463231A (en) * | 2015-12-30 | 2018-08-28 | 第三生物赞有限公司 | Prevention and therapeutic composition of the wooden extract of Han You Yellow paints as the climacteric syndrome of active ingredient |
| CN111356468A (en) * | 2017-07-25 | 2020-06-30 | 朝鲜大学校产学协力团 | Composition for preventing or treating fibrotic disease comprising extract of Rhus toxicodendron |
Non-Patent Citations (1)
| Title |
|---|
| 薛耀明: "内分泌与代谢学", 31 March 2018, pages: 773 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021172678A1 (en) | 2021-09-02 |
| KR20210108748A (en) | 2021-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marques et al. | Paullinia cupana: a multipurpose plant–a review | |
| US11166998B2 (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
| Chen et al. | Effect of lemon water soluble extract on hyperuricemia in a mouse model | |
| AU2006283051A1 (en) | Methods for managing adipocyte fat accumulation | |
| CA2627314C (en) | Composition for treating obesity comprising extract from white kidney beans, red kidney beans, and green tea leaves | |
| CN101815524A (en) | Preparation based on Morinda citrifolia Linn. leaf juice and leaf extract | |
| Masoodi et al. | A comprehensive review on fruit Aristotelia chilensis (Maqui) for modern health: towards a better understanding | |
| KR20160050108A (en) | Compositions for Improving Oral Hygiene comprising extracts derived from natural materials and Uses Thereof | |
| Sebai et al. | Modulating and opposite actions of two aqueous extracts prepared from Cinnamomum cassia L. bark and Quercus ilex L. on the gastrointestinal tract in rats | |
| Selfayan et al. | Inhibitory effect of Capparis spinosa extract on pancreatic alpha-amylase activity | |
| KR100492470B1 (en) | Composition for treating and preventing gout | |
| KR101890796B1 (en) | COMPOSITION FOR PREVENTING OR ALLEVIATING HANGOVER COMPRISING EXTRACTS OF GINGSENG BERRY, EXTRACTS OF Hovenia dulcis Thunberg AND MINERRAL CONCENTRATE | |
| Woldeyohannes et al. | Antidiarrheal and antisecretory effect of 80% hydromethanolic leaf extract of Moringa stenopetala baker f. In mice | |
| CN115135333A (en) | Composition for improving hyperuricemia comprising Rhus succedanea extract | |
| KR101470603B1 (en) | Manufacturing method of herbextract for removing harmful elements caused by smoking | |
| US20150335699A1 (en) | Composition for Prevention or Treatment of Acute Renal Failure Including Herbal Extract or Fraction Thereof as Active Ingredient | |
| KR20230138679A (en) | Composition for preventing or improving recognitive function disorder or memory disorder comprising fermented rhodiola sachalinesis | |
| Oso et al. | Assessment of in vitro biological properties of aqueous extracts of Murraya koenigii L. Spreng., Thymus vulgaris L., and Ocimum gratissimum L. leaves | |
| JP2006182706A (en) | Agent for increasing adiponectin amount in blood | |
| KR100759468B1 (en) | Composition for prevention and treatment of anti-gout comprising purple pigments isolated from purple sweet-potato | |
| Handayani et al. | Kecombrang (Etlingera elatior) Leaves Ethanol Extract Effect to Lens and Erythrocyte Aldose Reductase Activity in Wistar strain white rats (Rattus norvegicus) Streptozotocin induced | |
| KR101385191B1 (en) | Use of Cichorium intybus extracts for preventing, treating improving muscular atrophy | |
| KR101813200B1 (en) | MANUFACTURING METHOD OF BLACK GARLIC TABLET COMPRISING HIGH-CONTENT S-allylcysteine INCLUDING PINE NEEDLE | |
| EP2052728B1 (en) | Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia | |
| KR20050094278A (en) | A composition for preventing or treating adult diseases containing rei rhizoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |